MedPath

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center logo
🇺🇸United States
Ownership
Private
Established
1884-01-01
Employees
10K
Market Cap
-
Website
http://www.mskcc.org

Clinical Trials

1.9k

Active:392
Completed:1043

Trial Phases

6 Phases

Early Phase 1:36
Phase 1:423
Phase 2:626
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1442 trials with phase data)• Click on a phase to view related trials

Phase 2
626 (43.4%)
Phase 1
423 (29.3%)
Not Applicable
285 (19.8%)
Phase 3
67 (4.6%)
Early Phase 1
36 (2.5%)
Phase 4
5 (0.3%)

A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties

Not Applicable
Recruiting
Conditions
Blood Cancer
Lymphoma
Leukemia
Myeloma
First Posted Date
2025-07-08
Last Posted Date
2025-07-08
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
60
Registration Number
NCT07052916
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States

and more 4 locations

A Study of Surgery and Radiotherapy in People With Breast Cancer

Not Applicable
Not yet recruiting
Conditions
Metastatic Breast Cancer
HER2-positive Breast Cancer
Interventions
Drug: Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs
Procedure: Lumpectomy or mastectomy
Radiation: Radiotherapy
First Posted Date
2025-07-08
Last Posted Date
2025-07-08
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
162
Registration Number
NCT07053085
Locations
🇺🇸

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

A Study of Revaree Plus in People With Breast Cancer

Not Applicable
Recruiting
Conditions
Breast Cancer
Stage 0 Breast Cancer
Stage I Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer
Stage 0 Breast Carcinoma
Stage II Breast Carcinoma
Stage III Breast Carcinoma
Hormone-receptor-positive Breast Cancer
Hormone Receptor Positive Breast Carcinoma
Interventions
Drug: Revaree Plus
First Posted Date
2025-06-29
Last Posted Date
2025-06-29
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
60
Registration Number
NCT07042581
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States

and more 4 locations

A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

Phase 2
Not yet recruiting
Conditions
Lymphoma
Interventions
First Posted Date
2025-06-22
Last Posted Date
2025-07-04
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
27
Registration Number
NCT07030699
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors

Recruiting
Conditions
Survivorship
Recurrent
Recurrence
Cancer
Remission
First Posted Date
2025-06-22
Last Posted Date
2025-07-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
1000
Registration Number
NCT07030686
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 374
  • Next

News

YIV-906 Shows Promising Results in Phase 2b Trial for Advanced Hepatocellular Carcinoma with Hepatitis B

Yiviva's Phase 2b study demonstrated that YIV-906 plus sorafenib significantly improved median overall survival to 14.3 months versus 7.5 months with sorafenib alone in HBV-positive advanced hepatocellular carcinoma patients.

QBiotics' Tigilanol Tiglate Achieves 80% Response Rate in Soft Tissue Sarcoma Phase IIa Trial

QBiotics reported an 80% objective response rate in Stage 1 of its Phase IIa trial evaluating tigilanol tiglate in 10 patients with advanced soft tissue sarcoma.

NCT/UCC Dresden Launches Phase 2 Trial of Personalized mRNA Vaccine for Pancreatic Cancer

NCT/UCC Dresden becomes the only site in Saxony to offer patients access to BioNTech and Genentech's personalized mRNA vaccine Autogene Cevumeran for pancreatic cancer treatment.

Liso-cel Achieves 95.5% Response Rate in Relapsed/Refractory Marginal Zone Lymphoma

Lisocabtagene maraleucel (liso-cel) demonstrated a 95.5% overall response rate and 62.1% complete response rate in 66 patients with relapsed/refractory marginal zone lymphoma in the TRANSCEND FL trial.

Curadev and Memorial Sloan Kettering Expand Collaboration to Advance Novel STING Agonist CRD3874-SI

Curadev Pharma and Memorial Sloan Kettering Cancer Center are expanding their collaboration through MSK's Therapeutics Accelerator program to advance development of CRD3874-SI, a first-in-class allosteric STING agonist.

ImPact Biotech's Padeliporfin VTP Therapy Enables Surgical Resection in Previously Inoperable Pancreatic Cancer Patient

ImPact Biotech's first patient in a Phase 1 trial of Padeliporfin VTP therapy for locally advanced pancreatic ductal adenocarcinoma successfully underwent surgical resection after being initially deemed inoperable.

Minerva Biotechnologies Advances MUC1*-Targeted CAR-T Therapy with 1XX Mutations for Solid Tumors

Minerva Biotechnologies published research demonstrating that MUC1*-targeted CAR-T cells with 1XX mutations show increased persistence and ability to kill low antigen-expressing cancer cells in animal models.

Juri Biosciences Secures Global Rights to KLK2-Targeted T-Cell Engager for Metastatic Prostate Cancer in $210M Deal

Juri Biosciences, a TCG Labs Soleil portfolio company, has entered into a worldwide licensing agreement with EpimAb Biotherapeutics for exclusive global rights to a KLK2-targeted T-cell engager for metastatic prostate cancer treatment.

Pharmacists Take Central Role in Managing Novel Cancer Therapies as CAR-T and Bispecific Antibodies Transform Treatment Landscape

Pharmacists have evolved from traditional dispensing roles to comprehensive patient management in cancer care, particularly with novel therapies like CAR-T cell therapy and bispecific antibodies.

New Genetic Findings Challenge Traditional Understanding of Coats' Disease

Research led by Dr. David Abramson reveals that Coats' disease, traditionally considered unilateral, shows bilateral involvement when examined with fluorescein angiography, challenging long-held clinical beliefs.

© Copyright 2025. All Rights Reserved by MedPath